重症监护幸存2型糖尿病患者与共享照护随访门诊的效果:SWEET-AS随机对照先导研究
该前瞻性、随机、单中心先导研究纳入82例符合条件的2型糖尿病ICU幸存者(ICU停留≥5天且存活至ICU出院),42例(51%)被随机分配至出院后1个月参加重症-内分泌共享照护门诊或常规照护,主要终点为招募与保留率。6个月时4例(10%)退出、11例(26%)死亡;未退出者中仅18/38(47%)独立生活无支持,24例(63%)至少再住院一次。干预组21例中16例(76%)就诊;点估计未提示干预改善糖化血红蛋白(+5.6 mmol/mol;95%CI -6.3至17;P=.36)或生活质量(SF-36躯体汇总评分32[9] vs 32[7];P=1.0)。作者结论:该队列结局差,因参与率低和死亡率高,采用现有设计开展更大规模共享照护随访门诊试验似乎不可行。
要点
- 该先导研究纳入需ICU治疗≥5天且存活至ICU出院的2型糖尿病患者,18个月内82例符合条件者中42例(51%)被随机。
- 6个月时4例(10%)退出、11例(26%)死亡;未退出者中仅18/38(47%)独立生活无支持,24例(63%)至少再住院一次。
- 干预组21例中16例(76%)参加共享照护门诊;糖化血红蛋白变化+5.6 mmol/mol(95%CI -6.3至17;P=.36),未达统计学显著。
- 生活质量SF-36躯体汇总评分干预组32(9) vs 常规照护组32(7),P=1.0,点估计未提示改善。
- 作者认为,因参与率低和死亡率高,采用现有设计开展更大规模共享照护随访门诊试验似乎不可行。
适用人群与场景
- 纳入标准:2型糖尿病,需ICU治疗≥5天(混合内科-外科ICU),且存活至ICU出院。
- 场景:单中心ICU出院后随访,出院后1个月参加共享照护门诊(重症医学科-内分泌科联合门诊)或常规照护。
处置流程与药物剂量
- 干预组:出院后1个月参加共享照护重症-内分泌联合门诊;干预组21例中16例(76%)实际就诊。
- 对照组:接受常规照护。
- 6个月后评估结局,包括糖化血红蛋白、神经病变、肾病、生活质量、恢复就业、衰弱和医疗资源使用。
研究设计与关键结果
- 研究类型:前瞻性、随机、单中心先导研究,采用盲法结局评估;18个月内82例符合条件者中42例(51%)被随机。
- 主要终点为招募与保留率:42/82(51%)被招募;6个月评估前4例(10%)退出,11例(26%)死亡。
- 6个月时,未退出的38例中仅18例(47%)独立生活无支持,24例(63%)至少再住院一次。
- 糖化血红蛋白:干预组变化+5.6 mmol/mol(95%CI -6.3至17;P=.36),点估计未提示干预改善。
- 生活质量:SF-36躯体汇总评分干预组32(9) vs 常规照护组32(7),P=1.0。
- 作者结论:该队列结局差;因参与率低和死亡率高,采用现有设计开展更大规模共享照护随访门诊试验似乎不可行。
证据类型、等级与局限
- 证据类型:前瞻性、随机、单中心先导研究,盲法结局评估。
- 局限:作者指出因参与率低和死亡率高,采用现有设计开展更大规模试验似乎不可行;原文未报告其他局限性。
对床旁实践的改变
- 作者认为,对于ICU幸存且需≥5天重症监护的2型糖尿病患者,采用现有设计的共享照护随访门诊开展更大规模试验似乎不可行。
- 该人群中6个月时仅47%未退出者独立生活无支持、63%至少再住院一次,点估计未提示共享照护门诊改善糖化血红蛋白或生活质量。
指南或共识出处
- 澳大利亚新西兰临床试验注册中心(ANZCTR);注册号:ACTRN12616000206426;网址:www.anzctr.org.au
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Follow-up clinics after ICU admission have demonstrated limited benefit. However, existing trials have evaluated heterogeneous cohorts and used physicians who had limited training in outpatient care.
RESEARCH QUESTION: What are the effects of a "shared-care" intensivist-endocrinologist clinic for ICU survivors with type 2 diabetes on process measures and clinical outcomes 6 months after hospital discharge, and is it feasible to conduct a larger trial?
STUDY DESIGN AND METHODS: This was a prospective, randomized, single-center pilot study with blinded outcome assessment. Patients with type 2 diabetes, who required ≥ 5 days of ICU care (mixed medical-surgical ICU) and survived to ICU discharge, were eligible. Participants were randomized to attendance at the shared-care clinic 1 month after hospital discharge or usual care. Six months after hospital discharge, participants were assessed for outcomes including glycated hemoglobin, neuropathy, nephropathy, quality of life, return to employment, frailty, and health-care use. The primary outcome was participant recruitment and retention.
RESULTS: During an 18-month period, 42 of 82 eligible patients (51%) were recruited. Four participants (10%) withdrew before assessment at 6 months and 11 (26%) died. At 6 months, only 18 of 38 participants who did not withdraw (47%) were living independently without support, and 24 (63%) required at least one subsequent hospital admission. In the intervention group (n = 21), 16 (76%) attended the clinic. Point estimates did not indicate that the intervention improved glycated hemoglobin (+5.6 mmol/mol; 95% CI, -6.3 to 17; P = .36) or quality of life (36-Item Short Form Survey physical summary score, 32 [9] vs. 32 [7]; P = 1.0).
INTERPRETATION: Outcomes for ICU survivors with type 2 diabetes are poor. Because of low participation and high mortality, a larger trial of a shared-care follow-up clinic in this cohort, using the present design, does not appear feasible.
TRIAL REGISTRY: Australian New Zealand Clinical Trials Registry (ANZCTR); No.: ACTRN12616000206426; URL: www.anzctr.org.au.
参考来源
- Ali Abdelhamid Y, Phillips LK, White MG, et al. Survivors of Intensive Care With Type 2 Diabetes and the Effect of Shared-Care Follow-Up Clinics: The SWEET-AS Randomized Controlled Pilot Study. Chest. 2020. PMID: 32800818. doi:10.1016/j.chest.2020.08.011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。